Audit: QRS - Vitamin K2 for Health & Longevity
Audit conducted on 09/09/2026 19:22 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Spot-checked every populated span against the ER: protocol doses (ER 343–347), time-to-effect values (ER 164, 170, 398), all 10 monitoring rows (ER 434–443), cadence (ER 430), gates (ER 300–321), benefit/risk tiers (ER 154–216, 242–280), lede (ER 472–476). |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “Statins …, theoretical caution” mirrors ER 314; “unconfirmed elsewhere” in time_3_sub mirrors ER 170; “occasionally reported anecdotally and without trial support” mirrors ER 449. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | The VKA contraindication retains the “at any INR target of 2.0 or above, unless an anticoagulation clinic manages the combination explicitly” condition from ER 318; DOACs remain “no interaction” (ER 302). |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Gates draw only from ER Key Interactions & Contraindications (298–321); risks only from Potential Risks & Side Effects (238–280); no Benefit- or Risk-Modifying Factor is surfaced. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PubMed IDs, “et al.”, NCT identifiers, or brand names (MenaQ7, K2VITAL) occur anywhere in the QRS. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No named investigators, institutions, or organisations appear in the QRS. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Neutral, split-evidence framing carried over from the ER Conclusion (ER 472–478). |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Quantified targets and dose ranges alongside plain-language explanations; qualitative_item_5 explicitly de-catastrophises the absence of perceptible change. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Protocol cells describe what was used in trials rather than instructing; monitoring rows state what each marker detects. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No imperative instructions; footer disclaimer intact. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No occurrences of “recommend”, “advise”, or “should” in the document’s own voice. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the file. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical marker names carry their expansions inline (dp-ucMGP, ucOC, eGFR, DXA T-score, HbA1c). |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Gate and tier items are stripped to key facts; sub-lines are one or two clauses. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed — no “you”/”your” in the QRS. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Research-assay markers (dp-ucMGP, ucOC) and coronary calcium scoring are retained, which only a proactive audience would pursue. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Three-times-daily MK-4 dosing and multi-year monitoring horizons are presented without hedging on inconvenience. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Content assumes willingness to track biomarkers and sustain indefinite dosing. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | The lede names the split fracture/artery evidence and the form non-interchangeability rather than a simplified endorsement. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “anti-aging” does not occur; the header uses the ER canonical topic “Vitamin K2 for Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | No route-of-administration lay phrasing anywhere. Clinical register is used throughout the cards (“anticoagulant control”, “hypersensitivity”, “carboxylation”); the lede’s “blood-thinning drugs” / “average blood sugar” reproduce the ER Conclusion verbatim (ER 474, 476) under the item 7.4 plain-language requirement for [at_a_glance]. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All twelve strings match the template byte-for-byte (QRS lines 445, 491, 542, 575, 592, 616, 641, 645–647, 796 and the four tier <strong> labels). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | 69 uniquely-named spans present, no duplicates: the full template set with marker_#_* expanded to 1–10 and qualitative_item_# expanded to 1–5. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Diff of QRS lines 1–412 against template lines 1–410 shows only the metadata and <title> substitutions; the three <span website="..."> spans (evidence_review, audit, full_review) are unchanged. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No ER section feeding the QRS is empty — Benefits, Risks, Protocol, Interactions/Contraindications, and Monitoring are all populated. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol labels match ER 343/345/347 verbatim; interaction labels match ER 302–314 verbatim including their parenthetical drug lists. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Benefit and risk tier items reuse the ER subsection headings; monitoring markers reuse the ER biomarker column verbatim. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | Unicode scan for emoji ranges returns no matches; the ER’s ⚠️ Conflicted markers are correctly dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed against its ER source: 12 ER protocol bullets → 3 cells, 8 interaction bullets → 7 one-line items, magnitude paragraphs dropped entirely; the 10 monitoring rows are the minimum required by item 14.2. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14: the metadata comment opens on line 2, immediately after <!doctype html> on line 1. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- at line 3, closing --- at line 13; the descriptive text sits on line 2 before the opener. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; none of its values are echoed in <body> except the model name, which is the template’s own header_subline_model span. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:03" is quoted, and it contains a colon requiring YAML quoting. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: vitamin_k2_2026-0909-1544_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0909-1911. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9: qrs_filename: vitamin_k2_2026-0909-1544_Opus_QRS.html, matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys, including the added git_user and git_issue values, which are unquoted and untrimmed of nothing. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: Vitamin K2 for Health & Longevity - Quick Reference Sheet, matching ER frontmatter canonical_topic with the ampersand encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: Vitamin K2 for Health & Longevity. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: 09/09/2026, the MM/DD/YYYY rendering of 2026-0909-1911. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: Opus 5, matching the frontmatter value. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The header block (lines 415–428) is the template structure only; the ER’s “Also known as” line is not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Five sentences drawn from ER 472–476: mechanism, firmest findings, split evidence, form non-interchangeability, and the anticoagulant collision. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 59 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Calcium-routing → ER 472; firmest findings → ER 474; split evidence → ER 474; two non-interchangeable forms → ER 472; opposition to older blood thinners below one capsule → ER 476. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | “average blood sugar” for HbA1c, “blood-thinning drugs” for vitamin K antagonists, “bone density loss” for BMD decline; no acronyms beyond the intervention name itself. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No investigator names, years, cohort sizes, or p-values appear. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numeric effect estimates; “far below one capsule” is a qualitative comparison carried from ER 476. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All four items map to the “Populations who should avoid Vitamin K2” sub-list at ER 316–321. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | Complete four-for-four coverage: vitamin K antagonists, natto/PGA anaphylaxis, Child-Pugh C cirrhosis or untreated cholestasis, newborns. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Lines 578–587: four <li> elements inside the stop_items span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | ER’s trailing rationales are stripped: “in whom absorption and clotting effects are unpredictable” (ER 320) and “for whom vitamin K prophylaxis is a defined clinical protocol…” (ER 321) do not appear; no dash-led clauses remain. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | The INR 2.0 threshold and clinic-supervision exception (ER 318), the “fermentation-derived MK-7 specifically” scope (ER 319), and the Child-Pugh Class C staging (ER 320) are all retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in its contraindication list. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER does identify such populations (ER 316–321) and the section is correspondingly populated. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All seven items map to ER 302–314. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Seven of the eight ER interaction bullets are carried; the vitamin K antagonist bullet (ER 300) is correctly omitted because it already appears under Contraindications. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Lines 595–606: seven <li> elements inside the caution_items span. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | All mechanism sentences and mitigation clauses from ER 302–314 are stripped; what remains is the drug class plus, where the ER states one, the bare severity (“theoretical caution”, “no interaction”, “additive by design, not adverse”). No dash-led clauses. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Every ER drug list survives intact (cholestyramine/colestipol/colesevelam; orlistat/mineral oil; cefoperazone/cefotetan/rifampin; atorvastatin/rosuvastatin/simvastatin; apixaban/rivaroxaban/edoxaban/dabigatran), as does the 800 IU vitamin E threshold, with the ER’s “or international units” gloss trimmed for budget. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in its interaction list. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER identifies eight such bullets and the section is correspondingly populated. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells map to the first three bullets of the ER Therapeutic Protocol section (ER 343, 345, 347). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | The three dosing regimens are selected over the non-actionable bullets (Popularised by, Genetic considerations, Sex-based differences, Age considerations). |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies more than three actionable aspects; all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | 90–180 µg once daily / 360 µg once daily / 45 mg daily, each with the ER’s own conditions (fat-containing meal and indefinite continuation; reserved use with no advantage in healthy adults; 15 mg three times daily as a Japanese pharmaceutical dose). |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Bone mineral density (ER 398), glycaemic control (ER 164), and fracture incidence (ER 170) — the three High-tier benefits for which the ER states a horizon. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | All three are High-tier benefits and appear in the ER’s own High-tier order (ER 156, 162, 168). |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies more than three time-to-effect aspects; all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | 1–3 years, 12 weeks, and 2 years, each with an ER-sourced sub-line including the “nothing measurable happens on a scale of weeks” caveat (ER 398) and the “none ran past six months” limit (ER 164). |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information (ER 398 and the Benefits section), so the row is retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All ten items map to the ER subsection headings at ER 156–216. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans are present and populated, each matching the corresponding ER tier exactly (3 / 3 / 2 / 2 items). |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details. No mechanistic explanations, etc. Just the key fact. | 🟢 | Only the ER heading text is carried; all Magnitude paragraphs, “Net reading” sentences, and funding disclosures are dropped. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any benefits item. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER benefit tiers contain items, so no span needs hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All six items map to the ER subsection headings at ER 244–280. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans are present and populated, each matching the corresponding ER tier exactly (1 / 2 / 1 / 2 items). |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details. No mechanistic explanations, etc. Just the key fact. | 🟢 | Only the ER heading text is carried; the pooled relative risks, confidence intervals, and “Net reading: probably an artefact” are all dropped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any risks item. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER risk tiers contain items, so no span needs hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Rows reproduce the ER Monitoring Protocol & Defining Success biomarker table (ER 432–443) in its own order. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All 10 ER biomarkers present: INR, prothrombin time, dp-ucMGP, ucOC fraction, albumin-corrected serum calcium, 25-hydroxyvitamin D, eGFR, DXA T-score, coronary artery calcium score, HbA1c — with targets and “Why” text matching the ER columns verbatim. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Lines 786–790 condense ER 430: INR at 1 and 4 weeks after any change then the clinic interval; calcium and vitamin D at 3 months then every 6–12 months; bone density and calcium scoring not repeated inside 2 years. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Items map to ER 445–450, including the ER’s own caveat sentence that qualitative markers are weak and unreliable. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All four ER qualitative bullets are present: bruising/gum bleeding, gastrointestinal symptoms, dental calculus and tooth sensitivity, and absence of perceptible change. |
Issues 09/09/2026 19:22
Pass rate 100.00%. No issues found.
Issues 09/09/2026 19:18
- 11.2 — Speculative benefit in Time to Effect: The third Time-to-Effect set (lines 525-534) is given to “Improved carboxylation of extra-hepatic vitamin K proteins”, a Speculative-tier benefit whose own sub-text concedes it “is not a validated surrogate for any human outcome”, while the High-tier “Reduced Fracture Incidence” with its 24-month trial timeline (ER line 170) was passed over.
Fixes 09/09/2026 19:18
- 11.2 — Time to Effect third set replaced: Swapped the Speculative-tier “Improved carboxylation of extra-hepatic vitamin K proteins / 8–12 weeks” set for the High-tier “Reduced fracture incidence / 2 years”, so all three sets are now High-tier and ordered as the ER orders them.